Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs SkyWest Inc (SKYW) Price & Performance

Davita IncTrade
SkyWest IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs SkyWest Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while SkyWest Inc trades at $96.42 (market cap $3.75B). The key difference: Davita Inc is far larger — about 3× SkyWest Inc's market cap, and Davita Inc is more actively traded (582,204 versus 196,324). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and SkyWest Inc for 8 Days on average.

DVASKYW
Market Cap
$11.29B$3.75B
Volume
582,204196,324
Sector
HealthIndustrials
52-Week High
$240.96$115.94
52-Week Low
$103.87$78.40
Typical Hold Time
113 Days8 Days
Enterprise Value
$24.01B$5.54B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.

The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.

SkyWest Inc

SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with revenue growth from $4.1B in 2025 to $4.2B in 2026. Analyst consensus is bullish with a $112 price target, supported by fleet upgrades and flying agreements, though net income margin dipped to 9.78% in 2026.

The outlook is cautiously optimistic given strong analyst buy ratings and undervalued metrics like a P/E of 9.6, but risks include cost pressures, insider selling, and technical bearishness. Upside hinges on execution of growth initiatives amid competitive and operational headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
SKYW

No sentiment data available yet.

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About SkyWest Inc

SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.

Read more on SKYW →